SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT03383224

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Angina and Genotype-Guided Smoking Cessation In PRISM-GENOMICS

It has previously been shown that patients with coronary artery disease may have a harder time quitting smoking if they have a specific genetic profile and that these individuals have a better chance at quitting if they receive nicotine replacement therapy. The investigators hypothesize that determining which individuals with coronary artery disease should receive nicotine replacement therapy based on their genotype may improve the number of individuals who are able to quit smoking.This study randomizes treatment to that determined by the patient's genotype compared to standard, non-genotype-guided, treatment.

NCT03383224 Coronary Artery Disease Smoking Cessation
MeSH: Coronary Artery Disease Myocardial Ischemia Coronary Disease
HPO: Coronary artery atherosclerosis

3 Interventions

Name: genotype-guided therapy

Description: treatment based on patient's CHRNA5 rs16969968 genotype

Type: Other

Genotype-guided (A allele carriers) Genotype-guided (GG homozygotes)

Name: Nicotine patch

Type: Drug

Genotype-guided (A allele carriers) Standard (non-genotype guided) - NRT

Name: Smoking cessation counseling

Type: Behavioral

Genotype-guided (GG homozygotes) Standard (non-genotype guided)- counseling


Primary Outcomes

Description: Number of participants no longer smoking as assessed by telephone-administered questionnaire

Measure: Smoking Cessation

Time: 1 month after enrollment

Secondary Outcomes

Description: Number of participants no longer smoking as assessed by telephone-administered questionnaire

Measure: Smoking Cessation

Time: 6 months after enrollment

Description: Number of participants no longer smoking as assessed by telephone-administered questionnaire

Measure: Smoking Cessation

Time: 12 months after enrollment

Purpose: Other

Allocation: Randomized

Parallel Assignment


There is one SNP

SNPs


1 rs16969968

intubated) - Incarcerated - Complications of myocardial infarction (such as shock, hemodynamic instability, life- threatening infection, etc) - Women of child-bearing age with positive pregnancy test or who is breast feeding Coronary Artery Disease Smoking Cessation Coronary Artery Disease Myocardial Ischemia Coronary Disease In this study, the investigators propose to show the feasibility of incorporating genotype-guided therapy into post-MI smoking cessation therapy and/or smoking cessation therapy in patients with coronary artery disease (CAD) using the CHRNA5 rs16969968 variant as the pilot case.

The investigators propose to genotype ½ of PRISM-GENOMICs patients who are active smokers within 48 hours of admission and to guide their smoking cessation therapy based on CHRNA5 rs16969968 genotype (A allele carriers will be given pharmacologic therapy and GG homozygotes will be given counseling).



HPO Nodes


HPO:
Coronary artery atherosclerosis
Genes 34
TGFB2 TGFB3 TGFBR1 LDLRAP1 TGFBR2 MFAP5 APOA1 APOB ABCA1 MYH11 ELN LIPC FBN1 PRKG1 APOE PPARG ZMPSTE24 MYLK LMNA CYP7A1 SERPIND1 LDLR LOX MAT2A ABCG5 ABCG8 KCNJ5 ESR1 ZNF687 SMAD3 PCSK9 CEP19 ACTA2 FOXE3